Ponesimod - Actelion Pharmaceuticals

Drug Profile

Ponesimod - Actelion Pharmaceuticals

Alternative Names: ACT-128800; Compound 8bo - Actelion; R-3477; RG 3477

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Immunomodulators; Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Graft-versus-host disease
  • No development reported Immunological disorders; Plaque psoriasis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Immunological-disorders in Switzerland (PO)
  • 01 Nov 2017 Actelion Pharmaceuticals announces intention to submit NDA and MAA to US FDA and the EMA, respectively for relapsing multiple sclerosis between 2018 - 2021 (Johnson & Johnson pipeline, February 2018)
  • 25 Oct 2017 Interim pooled efficacy and safety data from a phase II and its extension trial in Multiple sclerosis presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS -2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top